Renew Bioscience, a commercial stage medical technology company, received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the Cerezen Device, a novel treatment for Mild Cognitive Impairment due to Alzheimer's Disease (MCI) and mild dementia of the Alzheimer's type (mild AD).
 
An important risk factor for cognitive impairment and dementia is poor vascular health, with cerebral blood flow and endothelial function believed to play a significant role in vascular health. The Renew Cerezen Device is a drug-free, non-invasive technology, designed to improve cerebral vascular health by enhancing circulation, simulating the physiological effects of vigorous exercise, and stimulating endothelial cell function through a series of treatment sessions.

 
The Cerezen Device utilizes ECP (External Counterpulsation) therapy that enhances blood flow and overall vascular efficiency. During the therapy, a technician wraps inflatable cuffs (similar to blood pressure cuffs) around the patient's calves, thighs and hips. The cuffs then synchronize to inflate and deflate between heartbeats. The external counter-pulsation process delivers more oxygenated blood to the body and brain. The process is soothing and relaxing for patients, like a massage. Cerezen must be used under the oversite of a healthcare professional.
 
Renew Bioscience COO, Tony Robinson, elaborates upon the recent development, "We are extremely pleased with the progress related to the Cerezen Device, specifically receiving the Breakthrough designation from the FDA. We truly believe that Cerezen represent a momentous potential advancement in the treatment of Alzheimer's and dementia, and we look forward to sharing some of the data from our recently completed pivotal study at the Clinical Trials on Alzheimer's Disease (CTAD) Conference next month in Boston."